Clinical Report: Office-Based Therapies Gain Ground in Glaucoma Care

Overview

Office-based therapies, particularly selective laser trabeculoplasty (SLT) and sustained drug delivery, are emerging as essential tools in glaucoma management. These approaches aim to lower intraocular pressure (IOP) while reducing reliance on traditional IOP-lowering drops, thereby improving patient compliance and outcomes.

Background

Glaucoma is a chronic condition that often requires a multifaceted treatment approach to manage effectively. Traditional therapies, including topical medications, can lead to poor adherence due to side effects and complexity. The shift towards office-based interventions like SLT and sustained-release drug delivery systems represents a significant change in the management paradigm, emphasizing earlier intervention and improved patient quality of life.

Data Highlights

No specific numerical data provided in the article.

Key Findings

• SLT and sustained drug delivery can reduce reliance on IOP-lowering drops.
• Long-term use of drops, especially those containing BAK, may compromise surgical outcomes.
• SLT remains underutilized as a first-line therapy despite evidence supporting its safety and efficacy.
• New technologies like direct selective laser trabeculoplasty (DSLT) can streamline treatment processes.
• Office-based therapies are foundational in a broader interventional strategy for glaucoma management.

Clinical Implications

Healthcare professionals should consider integrating office-based therapies into their glaucoma management protocols to enhance patient adherence and outcomes. Early intervention with SLT and sustained drug delivery can potentially delay the need for more invasive surgical options.

Conclusion

The adoption of office-based therapies marks a pivotal shift in glaucoma care, focusing on proactive management strategies that prioritize patient comfort and treatment efficacy.

References

1. Ophthalmology Management, 2023 -- Performing Office-Based Glaucoma Procedures
2. Glaucoma Physician, 2021 -- Individualizing Glaucoma Medical Management
3. Glaucoma Physician, 2025 -- Adapting Glaucoma Care to a Strained Workforce
4. NICE, 2025 -- Guidelines on Glaucoma Management
5. AAO, 2025 -- Primary Open-Angle Glaucoma Preferred Practice Pattern Guideline Summary
6. PubMed, 2026 -- Advancing glaucoma care: What's new in the 6th edition of the European Glaucoma Society guidelines
7. ophthalmology management — Adding Interventional DED Treatment to Your Practice
8. What is the long-term efficacy and safety of selective laser trabeculoplasty in the management of primary open-angle glaucoma?
9. Shedding LiGHT on Selective Laser Trabeculoplasty | JAMA Ophthalmology
10. Overview | Glaucoma: diagnosis and management | Guidance | NICE
11. AAO Primary Open-Angle Glaucoma Preferred Practice Pattern Guideline Summary - Guideline Central
12. Advancing glaucoma care: What's new in the 6th edition of the European Glaucoma Society guidelines - PubMed
13. Travoprost Intracameral Implant for Open-Angle Glaucoma or Ocular Hypertension: 12-Month Results of a Randomized, Double-Masked Trial - PMC
14. Glaukos Corporation - Glaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose® TR
15. Durysta: Package Insert / Prescribing Information / MOA